[Diagnosis, prophylaxis and therapeutic management of acute GVH: Guidelines from the SFGM-TC].

Date publication

février 2023

Journal

Bulletin du cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MARCAIS Ambroise

Tous les auteurs :
Souchet L, Masouridi S, Marçais A, Ibrahim A, Chauvel C, Turquet E, Derail M, Yakoub-Agha I, Crocchiolo R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36437127

Résumé

Acute GVHD is a potentially severe complication of hematopoietic stem cell transplantation, responsible for morbidity and mortality that can affect the prognosis after transplantation. Within the framework of the 12th workshop of practice harmonization of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC), diagnostic modalities of acute GVHD are updated. The conventional prevention (depending on donor, conditioning, and stem cell source) and treatment schemes (depending on affected organ and intensity) of aGVHD are clarified, and new therapeutic options are discussed.

Mots clés

Acute GVHD, Allogreffe, Bone Marrow Transplantation, GVH aiguë, Guidelines, Immunosuppressive therapy, Prophylaxis, Prévention, Recommandations, Traitement immunosuppresseur

Référence

Bull Cancer. 2023 02;110(2S):S79-S87